Bis(7,7-dimethyl-3-(6-methylpyrimidin-4-yl)-5,6-dihydro-4H-indazol-2-ide);4-methoxy-6-(5-methylpyrazol-2-id-3-yl)pyrimidine;bis(4-methyl-6-(5-methylpyrazol-2-id-3-yl)pyrimidine);4-methyl-6-[3-(trifluoromethyl)pyrazol-1-id-5-yl]pyrimidine;tetrakis(platinum(2+));bis(1,10,10-trimethyl-5-(6-methylpyrimidin-4-yl)-3-aza-4-azanidatricyclo[5.2.1.02,6]deca-2,5-diene)
C96H105F3N32OPt4 — CID 158411399
Data last refreshed: (MolForge compound catalog, from PubChem)
About Bis(7,7-dimethyl-3-(6-methylpyrimidin-4-yl)-5,6-dihydro-4H-indazol-2-ide);4-methoxy-6-(5-methylpyrazol-2-id-3-yl)pyrimidine;bis(4-methyl-6-(5-methylpyrazol-2-id-3-yl)pyrimidine);4-methyl-6-[3-(trifluoromethyl)pyrazol-1-id-5-yl]pyrimidine;tetrakis(platinum(2+));bis(1,10,10-trimethyl-5-(6-methylpyrimidin-4-yl)-3-aza-4-azanidatricyclo[5.2.1.02,6]deca-2,5-diene)
Bis(7,7-dimethyl-3-(6-methylpyrimidin-4-yl)-5,6-dihydro-4H-indazol-2-ide);4-methoxy-6-(5-methylpyrazol-2-id-3-yl)pyrimidine;bis(4-methyl-6-(5-methylpyrazol-2-id-3-yl)pyrimidine);4-methyl-6-[3-(trifluoromethyl)pyrazol-1-id-5-yl]pyrimidine;tetrakis(platinum(2+));bis(1,10,10-trimethyl-5-(6-methylpyrimidin-4-yl)-3-aza-4-azanidatricyclo[5.2.1.02,6]deca-2,5-diene) (PubChem CID 158411399) has the molecular formula C96H105F3N32OPt4 and a molecular weight of 2560.42 g/mol. Its IUPAC name is bis(7,7-dimethyl-3-(6-methylpyrimidin-4-yl)-5,6-dihydro-4H-indazol-2-ide);4-methoxy-6-(5-methylpyrazol-2-id-3-yl)pyrimidine;bis(4-methyl-6-(5-methylpyrazol-2-id-3-yl)pyrimidine);4-methyl-6-[3-(trifluoromethyl)pyrazol-1-id-5-yl]pyrimidine;tetrakis(platinum(2+));bis(1,10,10-trimethyl-5-(6-methylpyrimidin-4-yl)-3-aza-4-azanidatricyclo[5.2.1.02,6]deca-2,5-diene).
Molecular Properties
| Compound Name | Bis(7,7-dimethyl-3-(6-methylpyrimidin-4-yl)-5,6-dihydro-4H-indazol-2-ide);4-methoxy-6-(5-methylpyrazol-2-id-3-yl)pyrimidine;bis(4-methyl-6-(5-methylpyrazol-2-id-3-yl)pyrimidine);4-methyl-6-[3-(trifluoromethyl)pyrazol-1-id-5-yl]pyrimidine;tetrakis(platinum(2+));bis(1,10,10-trimethyl-5-(6-methylpyrimidin-4-yl)-3-aza-4-azanidatricyclo[5.2.1.02,6]deca-2,5-diene) |
|---|---|
| PubChem CID | 158411399 |
| Molecular Formula | C96H105F3N32OPt4 |
| Molecular Weight | 2560.42 g/mol |
| Exact Mass | 2558.77 |
| IUPAC Name | bis(7,7-dimethyl-3-(6-methylpyrimidin-4-yl)-5,6-dihydro-4H-indazol-2-ide);4-methoxy-6-(5-methylpyrazol-2-id-3-yl)pyrimidine;bis(4-methyl-6-(5-methylpyrazol-2-id-3-yl)pyrimidine);4-methyl-6-[3-(trifluoromethyl)pyrazol-1-id-5-yl]pyrimidine;tetrakis(platinum(2+));bis(1,10,10-trimethyl-5-(6-methylpyrimidin-4-yl)-3-aza-4-azanidatricyclo[5.2.1.02,6]deca-2,5-diene) |
| SMILES | COc1cc(-c2cc(C)n[n-]2)ncn1.Cc1cc(-c2[n-]nc3c2C2CCC3(C)C2(C)C)ncn1.Cc1cc(-c2[n-]nc3c2C2CCC3(C)C2(C)C)ncn1.Cc1cc(-c2[n-]nc3c2CCCC3(C)C)ncn1.Cc1cc(-c2[n-]nc3c2CCCC3(C)C)ncn1.Cc1cc(-c2cc(C(F)(F)F)n[n-]2)ncn1.Cc1cc(-c2cc(C)n[n-]2)ncn1.Cc1cc(-c2cc(C)n[n-]2)ncn1.[Pt+2].[Pt+2].[Pt+2].[Pt+2] |
| InChI | InChI=1S/2C16H19N4.2C14H17N4.C9H6F3N4.C9H9N4O.2C9H9N4.4Pt/c2*1-9-7-11(18-8-17-9)13-12-10-5-6-16(4,15(10,2)3)14(12)20-19-13;2*1-9-7-11(16-8-15-9)12-10-5-4-6-14(2,3)13(10)18-17-12;1-5-2-6(14-4-13-5)7-3-8(16-15-7)9(10,11)12;1-6-3-8(13-12-6)7-4-9(14-2)11-5-10-7;2*1-6-3-8(11-5-10-6)9-4-7(2)12-13-9;;;;/h2*7-8,10H,5-6H2,1-4H3;2*7-8H,4-6H2,1-3H3;2-4H,1H3;3-5H,1-2H3;2*3-5H,1-2H3;;;;/q8*-1;4*+2 |
| InChIKey | GZJAIVUFMKVUKX-UHFFFAOYSA-N |
| XLogP | 15.65 |
| TPSA | 431.39 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 25 |
| Rotatable Bonds | 9 |
| Heavy Atoms | 136 |
| Complexity | — |
Lipinski Rule of Five
3 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 2560.42 |
| LogP ≤ 5 | 15.65 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 25 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 158411399 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.